A detailed history of Royal Bank Of Canada transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 9,019 shares of JANX stock, worth $506,326. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,019
Previous 24,519 63.22%
Holding current value
$506,326
Previous $1.03 Million 60.18%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$35.29 - $50.26 $546,995 - $779,030
-15,500 Reduced 63.22%
9,019 $409,000
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $805,371 - $1.49 Million
22,932 Added 1444.99%
24,519 $1.03 Million
Q1 2024

Nov 05, 2024

SELL
$7.93 - $49.75 $181,850 - $1.14 Million
-22,932 Reduced 93.53%
1,587 $59,000
Q1 2024

May 15, 2024

SELL
$7.93 - $49.75 $24,662 - $154,722
-3,110 Reduced 66.21%
1,587 $59,000
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $7,604 - $15,209
1,300 Added 38.27%
4,697 $50,000
Q3 2023

Nov 14, 2023

BUY
$9.56 - $14.0 $15,429 - $22,596
1,614 Added 90.52%
3,397 $34,000
Q2 2023

Aug 14, 2023

BUY
$11.08 - $15.92 $9,118 - $13,102
823 Added 85.73%
1,783 $21,000
Q1 2023

May 15, 2023

SELL
$11.25 - $22.21 $13,736 - $27,118
-1,221 Reduced 55.98%
960 $11,000
Q4 2022

Feb 14, 2023

BUY
$11.1 - $18.26 $21,611 - $35,552
1,947 Added 832.05%
2,181 $28,000
Q3 2022

Nov 14, 2022

BUY
$10.82 - $16.84 $1,482 - $2,307
137 Added 141.24%
234 $3,000
Q2 2022

Aug 15, 2022

SELL
$9.52 - $15.65 $9,472 - $15,571
-995 Reduced 91.12%
97 $1,000
Q1 2022

May 16, 2022

SELL
$13.24 - $20.24 $24,626 - $37,646
-1,860 Reduced 63.01%
1,092 $16,000
Q4 2021

Feb 14, 2022

BUY
$15.44 - $27.32 $1,775 - $3,141
115 Added 4.05%
2,952 $58,000
Q3 2021

Nov 15, 2021

BUY
$20.7 - $34.69 $31,815 - $53,318
1,537 Added 118.23%
2,837 $61,000
Q2 2021

Aug 16, 2021

BUY
$18.58 - $25.37 $24,153 - $32,981
1,300 New
1,300 $32,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.